Introduction {#s1}
============

Placebos are an essential component of randomised controlled trials (RCTs). They are used to control for bias, contextual and psychological components of treatment and thus isolate the speciﬁc effects of the intervention under investigation. Administering placebos to patients can elicit both beneficial and adverse ('nocebo') effects. Many factors are now known to impact on the strength of the placebo response, including factors associated with the healthcare professional administering treatment, the patient receiving treatment and their therapeutic relationship.[@R1] Characteristics of the intervention itself, such as medication colour, the form and frequency of administration also influence the strength of placebo response.[@R5] Nocebo effects are typically linked to patient expectations derived from side-effect warnings and can be conditioned from previous adverse events.[@R9] Common nocebo effects include nausea, stomach pains, itching, bloating, depression and sleep problems.[@R10]

It is important that potential trial participants know about placebo and nocebo effects. At minimum an accurate knowledge of the possible benefits and adverse effects of placebos is necessary to ensure consent to take part in an RCT is adequately informed. In addition, people's understanding of, and attitudes towards, placebos may influence their willingness to participate in placebo-controlled RCTs[@R11] and thus could have implications for fair access. However, information leaflets used in RCTs often provide incomplete or inaccurate information about placebos. Bishop *et al* found that only 1 of 45 participant  information leaflets used in major RCTs in the UK mentioned that placebos may elicit beneficial effects and only four mentioned that placebos can elicit adverse effects.[@R13]

It is necessary to assess people's baseline knowledge of placebos (ie, before participating in any trial recruitment activities) in order to identify common gaps in knowledge and thus specify the placebo characteristics that should be prioritised for inclusion in participant information leaflets. However, little is known about the public's knowledge of placebos and placebo effects. We surveyed people with back pain to examine current levels of placebo knowledge and identify knowledge gaps. To the authors' knowledge this is the first such study. The objective was to inform improvements to informed consent procedures.

Methods {#s2}
=======

Design and measures {#s2a}
-------------------

A web-based cross-sectional survey was conducted. Fifteen true-false items assessed knowledge of placebos (for items, see [table 1](#T1){ref-type="table"}). Items were developed after consulting with experts in placebo research and examining relevant literature. The questionnaire was pretested with 10 lay volunteers and modified based on their feedback. The survey also assessed demographic characteristics; experience of/sources of knowledge about placebos (to permit an initial assessment of the validity of our knowledge questionnaire); and history and severity of back pain and its impact on daily living, using the validated reliable Chronic Pain Grade Questionnaire.[@R14] Participants also completed a 15-item acupuncture questionnaire (reported separately[@R15]).

###### 

Participants' knowledge about placebos

  Item                                                                                                               Correct answer   Total % correct (n)   Read/heard about placebos (n=143)[†](#tblfn2){ref-type="fn"} % correct (n)   Not read/heard about placebos (n=64)[†](#tblfn2){ref-type="fn"} % correct (n)
  ------------------------------------------------------------------------------------------------------------------ ---------------- --------------------- ---------------------------------------------------------------------------- -------------------------------------------------------------------------------
  A pill with aspirin in it is called a 'placebo' pill                                                               False            98.1% (206)           98.6% (141)                                                                  96.9% (62)
  The placebo effect can work because of people's expectations                                                       True             95.2% (200)           99.3% (142)                                                                  85.9% (55)\*\*
  Placebo treatments are only effective for people who are not very intelligent                                      False            96.7% (203)           97.9% (140)                                                                  93.8% (60)
  Placebo treatments can help to treat pain conditions                                                               True             79.5% (167)           82.5% (118)                                                                  71.9% (46)
  Placebo treatments do not help to relieve any medical symptoms                                                     False            72.9% (153)           76.2% (109)                                                                  65.6% (42)
  Placebo pain treatments only relieve imaginary pain (ie, pain that was not real in the first place)                False            85.2% (179)           89.5% (128)                                                                  75.0% (48)\*\*
  A pill with no medicine in it is called a 'placebo' pill                                                           True             91.9% (193)           97.9% (140)                                                                  78.1% (50)\*\*
  The placebo effect can work because of conditioning                                                                True             74.3% (156)           74.8% (107)                                                                  73.4% (47)
  Real changes in the brain can occur when you receive a placebo (such as the release of chemicals called opioids)   True             83.8% (176)           88.1% (126)                                                                  73.4% (47)\*
  Placebo effects are imaginary and have no real physical effects on our body                                        False            81.0% (170)           83.2% (119)                                                                  76.6% (49)
  Placebo effects only occur in experiments and research trials                                                      False            86.2% (181)           90.2% (129)                                                                  76.6% (49)\*\*
  A placebo pill can have side effects                                                                               True             31.9% (67)            34.3% (49)                                                                   28.1% (18)
  The placebo effect can help us to get better during normal medical treatments                                      True             79.5% (167)           83.9% (120)                                                                  68.8% (44)\*
  The colour of a placebo pill can change how effective it is                                                        True             55.2% (116)           60.1% (86)                                                                   43.8% (28)\*
  Placebo treatments are only effective for people who lie about their symptoms                                      False            96.7% (203)           99.3% (142)                                                                  90.6% (58)\*\*

\*p\<0.05, \*\*p\<0.01, significant χ^2^.

†Three participants did not specify whether they had previously read or heard about placebos.

Participants {#s2b}
------------

We surveyed adults with a history of back pain, as back pain is prevalent[@R16] and placebos have demonstrated pronounced effects in chronic pain conditions.[@R17]

Procedure {#s2c}
---------

Ethical approval was given by the University of Southampton Psychology Ethics Committee.

Fifteen UK universities invited staff and students to participate via email. The study was also advertised on social media sites pertaining to back pain and to local businesses. Adults who had 'had back pain' were invited to take part in a 'short (10 min) online quiz' about alternative treatments for back pain. On clicking a link participants reached an information page presenting study details and a tick-box to indicate consent. Participants then completed the survey.

Data were imported into SPSS V.22 and summarised using descriptive statistics. Analysis of variance, t-test, χ^2^ test and Spearman's correlation test assessed whether knowledge of placebos was related to previous experience of receiving placebos, having read or heard about placebos, gender, age, ethnicity, highest qualification and back pain characteristics.

Results {#s3}
=======

Participant characteristics {#s3a}
---------------------------

Two hundred and twenty-six people participated between July and October 2014. Data were excluded from 16 individuals who failed to complete any placebo knowledge items, leaving 210 participants. One hundred and thirty-six participants were female (67.7%) and 65 were male (32.3%), aged 18--74 years (M=35, SD=14.05) (9 skipped these items). All participants reported back pain: 100% ever had back pain, 86.7% (n=182) in the past 6 months and 44.3% (n=93) currently. Of those reporting current back pain, average pain intensity was mild (M=3.4, SD=2.16) (see [table 2](#T2){ref-type="table"} for additional characteristics).

###### 

Participant characteristics

                                      Number (n)   Per cent (%)
  ----------------------------------- ------------ --------------
   Gender\*                                        
   Female                             136          67.7
   Male                               65           32.3
  Ethnic origin                                    
   White British                      137          65.2
   Other White background             39           18.6
   Asian or Asian British             9            4.3
   Chinese                            7            3.3
   Other                              16           7.7
   Preferred not to state ethnicity   2            1.0
  Occupation                                       
   Student                            66           31.4
   Administrator/secretary            27           12.9
   Academic                           25           11.9
   Postgraduate student               21           10.0
   Researcher                         19           9.0
   Teaching                           12           5.7
   Healthcare professional            8            3.8
   Currently not working/retired      7            3.3
   Technician/programmer              7            3.3
   Care work                          4            1.9
   Engineering                        2            1.0
   Other                              12           5.7
  Highest level of education                       
   Secondary school                   10           4.8
   Some college                       31           14.8
   Bachelor's degree                  50           23.8
   Master's degree                    58           27.6
   Doctoral degree                    44           21.0
   Other                              17           8.1

  Pain in past 6 months[†](#tblfn4){ref-type="fn"}   Mean   SD
  -------------------------------------------------- ------ ------
   Intensity                                         4.23   1.96
   Interference in daily activities                  3.83   2.57
   Interference in recreational activities           3.08   2.70
   Interference in work activities                   2.93   2.61

\*Nine participants did not specify their gender.

†Items answered on a 0--10 scale, where 10 indicates highest levels of pain intensity/interference.

Experiences of placebos {#s3b}
-----------------------

Only nine participants (4.3%) had previously received a placebo as part of an RCT, but 68.1% (n=143) reported having previously read or heard about placebos, via friends and family, school/university, general knowledge, books, media and/or the internet.

Knowledge {#s3c}
---------

Participants answered between 4 and 15 knowledge items correctly (M=12.07; SD=2.35) (see [table 1](#T1){ref-type="table"}). Key gaps in placebo knowledge were identified; 31.9% knew that a placebo pill can have side effects and 55.2% knew that the colour of a placebo pill can change how effective it is.

The nine participants who had previously received placebo treatment as part of an RCT (M=12.22, SD=1.64) had similar knowledge scores to the 201 who had not (M=12.06, SD=2.39) (p=0.841). However, the 143 participants who reported previously reading or hearing about placebos had significantly higher scores (M=12.55, SD=2.15) than the 67 who indicated they had not read or heard about placebos (M=10.97, SD=2.49) (t=4.663, df=205, p\<0.001).

There were just two differences in knowledge by sociodemographic and clinical characteristics. Participants who identified as white British had higher placebo knowledge scores than other ethnicities combined (M=12.47 (SD=2.18) and M=11.33 (SD=2.50), respectively; t=3.422, df=208, p=0.001). Participants who reported less intense pain during the previous 6 months had higher placebo knowledge scores than those who reported more intense pain (r~s~=−0.210; p\<0.01).

Discussion {#s4}
==========

Placebos are an important component of RCTs used to elucidate the speciﬁc effects of an intervention under investigation. For informed consent to be valid, trial participants need an accurate knowledge of placebos; this should minimally include an understanding that placebos can have both beneficial and adverse effects.[@R18] Our community-based survey of people with back pain found relatively high knowledge overall but only a small minority of participants knew that placebos could have adverse, that is, nocebo, effects. Evidence from meta-analysis suggests as many as 52% of RCT participants receiving a placebo may experience nocebo effects.[@R19] However, just 31.9% of our participants knew that a placebo can have side effects. Earlier studies elsewhere reported similar findings: 4.8% of general practitioner patients in New Zealand agreed that placebos can cause bad side effects[@R20] and 7.7% of patients recruited from a rheumatology clinic  in France believed placebos can induce adverse effects.[@R21] Our study updates and extends this work, suggesting that the UK patients would also benefit from receiving information about nocebo effects before taking part in a placebo-controlled RCT.

A lack of placebo knowledge among potential trial participants has implications for the ethical principle of autonomy, and consequently participants' ability to provide full informed consent. Respect for autonomy requires potential participants to have sufficient information to enable them to make an informed decision regarding participation. In particular, the Declaration of Helsinki[@R18] requires volunteers to be informed about the potential benefits and harms of participation. The knowledge gaps identified within the present study, combined with the limited descriptions of placebos in participant information sheets found previously,[@R13] suggest that in many cases participants do not have an adequate understanding of the potential benefits and harms of placebos before consenting to placebo-controlled RCTs. This would appear to violate the principle of autonomy, and may question the ethical validity of consent.[@R22]

There is increasing awareness that ethical practices, such as the content of participant information sheets, should be grounded in empirical data.[@R23] However, there remains a dearth of published research to inform investigators and research ethics committees. This study was strengthened by using evidence-based items to assess placebo knowledge objectively. The fact that participants who had previously read or heard about placebos scored higher than other participants provides initial evidence for the construct validity of the knowledge questionnaire.

Selection bias is a limitation; participants were more highly educated than the general UK population (almost 50% possessed a postgraduate qualification). This may have driven the high placebo knowledge scores and a more representative sample might have exhibited less knowledge; indeed, even lower levels of knowledge about nocebo effects have been reported by others.[@R20] However, educational attainment was not related to placebo knowledge in this sample.

Research ethics committees and investigators should prioritise amending informed consent documentation and procedures to explain that participants in the placebo arm might experience beneficial and adverse effects. Our findings suggest that while volunteers may have some existing knowledge that placebos can elicit beneficial effects, they are far less likely to appreciate their potential to elicit adverse effects. Adding information about nocebo effects to participant information sheets and associated discussions might therefore increase participants' capacity to provide ethically valid informed consent. Future research could evaluate placebo knowledge gaps in other patient groups and develop resources and guidelines to improve the provision of patient information about placebo and nocebo effects. In the meantime, we recommend that research ethics committees apply greater scrutiny to the description of placebos in participant information sheets.
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